{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:57:59Z","timestamp":1794535079033,"version":"4.9.1"},"reference-count":507,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007480","name":"University of Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["BFU2017-82494-P"],"award-info":[{"award-number":["BFU2017-82494-P"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["PID2020-115823GB-I00"],"award-info":[{"award-number":["PID2020-115823GB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.arr.2021.101496","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T01:59:02Z","timestamp":1634867942000},"page":"101496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":299,"special_numbering":"C","title":["Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: a systematic review"],"prefix":"10.1016","volume":"72","author":[{"given":"Danko","family":"Jeremic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Jim\u00e9nez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Navarro-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2021.101496_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-020-00656-y","article-title":"Diagnosis and management of seizures in neurodegenerative diseases","volume":"23","author":"Adan","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00702-003-0024-8","article-title":"EEG coherence in Alzheimer\u2019s dementia","volume":"110","author":"Adler","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.arr.2021.101496_bib3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.neuint.2008.01.005","article-title":"Overactivation of calcineurin induced by amyloid-beta and prion proteins","volume":"52","author":"Agostinho","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.arr.2021.101496_bib4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/ejn.12499","article-title":"Synapto-depressive effects of amyloid beta require PICK1","volume":"39","author":"Alfonso","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.exger.2016.11.001","article-title":"APOEepsilon4 impacts up-regulation of brain-derived neurotrophic factor after a six-month stretch and aerobic exercise intervention in mild cognitively impaired elderly African Americans: a pilot study","volume":"87","author":"Allard","year":"2017","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.arr.2021.101496_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092313","article-title":"Natural compounds for Alzheimer\u2019s disease therapy: a systematic review of preclinical and clinical studies","volume":"20","author":"Andrade","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer\u2019s disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2021.101496_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","article-title":"Targeting neuroinflammation to treat Alzheimer\u2019s disease","volume":"31","author":"Ardura-Fabregat","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2021.101496_bib9","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib10","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1073\/pnas.0911531107","article-title":"Cross-frequency coupling supports multi-item working memory in the human hippocampus","volume":"107","author":"Axmacher","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib11","unstructured":"Alzforum.org, 2021. Aduhelm. https:\/\/www.alzforum.org\/therapeutics\/aduhelm [Accesed 18.08.2021]."},{"key":"10.1016\/j.arr.2021.101496_bib12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jagp.2016.04.004","article-title":"Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels","volume":"24","author":"Babulal","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13195-020-00710-6","article-title":"Effect of APOE epsilon4 genotype on amyloid-beta and tau accumulation in Alzheimer\u2019s disease","volume":"12","author":"Baek","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.nicl.2015.02.009","article-title":"Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance","volume":"7","author":"Bakker","year":"2015","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.arr.2021.101496_bib16","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1039\/C7SC01743J","article-title":"Amyloid \u03b2-peptides 1-40 and 1-42 form oligomers with mixed \u03b2-sheets","volume":"8","author":"Baldassarre","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.653334","article-title":"Role of neuron and glia in Alzheimer\u2019s disease and associated vascular dysfunction","volume":"13","author":"Bandyopadhyay","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JAD-150650","article-title":"Diminished CRE-induced plasticity is linked to memory deficits in familial Alzheimer\u2019s disease mice","volume":"50","author":"Bartolotti","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101496_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2018.07.215","article-title":"Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease","volume":"15","author":"Bell","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib22","article-title":"Apolipoprotein E4-driven effects on inflammatory and neurotrophic factors in peripheral extracellular vesicles from cognitively impaired, no dementia participants who converted to Alzheimer's disease","volume":"7","author":"Ben Khedher","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hipo.22955","article-title":"Amyloid fibrils induce dysfunction of hippocampal glutamatergic silent synapses","volume":"28","author":"Bie","year":"2018","journal-title":"Hippocampus"},{"key":"10.1016\/j.arr.2021.101496_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101496_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2016.06.1207","article-title":"P2-003: Clinical trial design of cread: a randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate crenezumab treatment in patients with prodromal-to-mild Alzheimer\u2019s disease","volume":"12","author":"Blaettler","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-010-0705-y","article-title":"Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer\u2019s disease","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101496_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fncel.2016.00166","article-title":"Canonical and non-canonical reelin signaling","volume":"10","author":"Bock","year":"2016","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3233\/JAD-2009-1191","article-title":"BDNF genetic variations increase the risk of Alzheimer\u2019s disease-related depression","volume":"18","author":"Borroni","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2018.00043","article-title":"Understanding the role of adenosine A2AR heteroreceptor complexes in neurodegeneration and neuroinflammation","volume":"12","author":"Borroto-Escuela","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnagi.2018.00180","article-title":"APOE and Alzheimer\u2019s disease: neuroimaging of metabolic and cerebrovascular dysfunction","volume":"10","author":"Brandon","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib34","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.1021\/ja503535m","article-title":"The N-terminal region of amyloid beta controls the aggregation rate and fibril stability at low pH through a gain of function mechanism","volume":"136","author":"Brannstrom","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.arr.2021.101496_bib35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3233\/JAD-180675","article-title":"Clinical evaluation of amyloid-related imaging abnormalities in Bapineuzumab phase III studies","volume":"66","author":"Brashear","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40261-017-0549-5","article-title":"Pharmacokinetics of cromolyn and Ibuprofen in healthy elderly volunteers","volume":"37","author":"Brazier","year":"2017","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.arr.2021.101496_bib37","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","article-title":"Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice","volume":"24","author":"Brecht","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/hmg\/5.10.1589","article-title":"cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein","volume":"5","author":"Bressler","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2021.101496_bib39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jalz.2018.04.010","article-title":"Sex, amyloid, and APOE epsilon4 and risk of cognitive decline in preclinical Alzheimer\u2019s disease: findings from three well-characterized cohorts","volume":"14","author":"Buckley","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib40","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1021\/acs.jmedchem.5b01960","article-title":"Gamma secretase modulators: new Alzheimer\u2019s drugs on the horizon?","volume":"59","author":"Bursavich","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.arr.2021.101496_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","article-title":"Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease","volume":"36","author":"Burstein","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2021.101496_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-14-12","article-title":"Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease","volume":"14","author":"Burstein","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14283\/jpad.2018.18","article-title":"Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib44","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0429","article-title":"Impairments of neural circuit function in Alzheimer\u2019s disease","volume":"371","author":"Busche","year":"2016","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib45","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/nn.4137","article-title":"Rescue of long-range circuit dysfunction in Alzheimer\u2019s disease models","volume":"18","author":"Busche","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.280","article-title":"Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models","volume":"7","author":"Cacciottolo","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib47","series-title":"Eisai and Biogen to Discontinue Phase III Clinical Studies of BACE Inhibitor Elenbecestat in Early Alzheimer\u2019s Disease","author":"Caouette","year":"2019"},{"key":"10.1016\/j.arr.2021.101496_bib48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.arr.2021.101496_bib49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer\u2019s disease","volume":"55","author":"Cebers","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib50","first-page":"201","article-title":"Structural aspects of Alzheimer\u2019s disease immunotherapy targeted against amyloid-beta peptide","volume":"119","author":"Cehlar","year":"2018","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.arr.2021.101496_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fnmol.2019.00141","article-title":"Hyperpolarization-activated cyclic nucleotide-gated channels: an emerging role in neurodegenerative diseases","volume":"12","author":"Chang","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib52","article-title":"ApoE Genotype-Dependent Response to Antioxidant and Exercise Interventions on Brain Function","volume":"9","author":"Chaudhari","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.arr.2021.101496_bib53","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.arr.2021.101496_bib54","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1073\/pnas.0914984107","article-title":"ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling","volume":"107","author":"Chen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.118.209130","article-title":"Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab","volume":"60","author":"Chiao","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.arr.2021.101496_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1528-1157.2003.27302.x","article-title":"Interictal epileptic spiking during sleep and wakefulness in mesial temporal lobe epilepsy: a comparative study of scalp and foramen ovale electrodes","volume":"44","author":"Clemens","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.arr.2021.101496_bib57","unstructured":"ClinicalTrials.gov, 2020c. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU001 (DIAN-TU) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760005?term=solanezumab&draw=2&rank=11\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib58","unstructured":"ClinicalTrials.gov, 2021j. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)."},{"key":"10.1016\/j.arr.2021.101496_bib59","unstructured":"ClinicalTrials.gov, {C}2020d{C}. Effect of CT1812 Treatment on Brain Synaptic Density \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03493282\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib60","unstructured":"ClinicalTrials.gov, 2019c. ELND005 in Patients With Mild to Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00568776\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib61","unstructured":"ClinicalTrials.gov, {C}2019d{C}. ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00934050\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib62","unstructured":"ClinicalTrials.gov, {C}2017b{C}. Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03486938\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib63","unstructured":"ClinicalTrials.gov, {C}2017c{C}. Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02221947\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib64","unstructured":"ClinicalTrials.gov, 2017a. Development of NIC5\u201315 in the Treatment of Alzheimer's Disease \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00470418\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib65","unstructured":"ClinicalTrials.gov, 2019a. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib66","unstructured":"ClinicalTrials.gov, {C}2019b{C}. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)."},{"key":"10.1016\/j.arr.2021.101496_bib67","unstructured":"ClinicalTrials.gov, 2018a. A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03093519\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib68","unstructured":"ClinicalTrials.gov, {C}2018b{C}. A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02431468\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib69","unstructured":"ClinicalTrials.gov, {C}2020a{C}. AHEAD 3\u201345 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid."},{"key":"10.1016\/j.arr.2021.101496_bib70","unstructured":"ClinicalTrials.gov, {C}2021m{C}. A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03887455\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib71","unstructured":"ClinicalTrials.gov, {C}2020b{C}. Bryostatin Treatment of Moderately Severe Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04538066\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib72","unstructured":"ClinicalTrials.gov, 2021n. Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease."},{"key":"10.1016\/j.arr.2021.101496_bib73","unstructured":"ClinicalTrials.gov, {C}2021k{C}. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437511\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib74","unstructured":"ClinicalTrials.gov, {C}2021i{C}. A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S1) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02565511\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib75","unstructured":"ClinicalTrials.gov, 2021h. Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03806478\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib76","unstructured":"ClinicalTrials.gov, {C}2020e{C}. An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03531710\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib77","unstructured":"ClinicalTrials.gov, {C}2020f{C}. A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640077\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib78","unstructured":"ClinicalTrials.gov, 2019g. SAD\/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02036645\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib79","unstructured":"ClinicalTrials.gov, {C}2019h{C}. Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461276\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib80","unstructured":"ClinicalTrials.gov, 2019e. Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) (LAPSE) \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04004702\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib81","unstructured":"ClinicalTrials.gov, {C}2019f{C}. Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A\u03b2 IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease (PRIME) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01677572\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib82","unstructured":"ClinicalTrials.gov, 2021l. A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease (GREEN MEMORY) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04520412\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib83","unstructured":"ClinicalTrials.gov, {C}2021e{C}. Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04735536\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib84","unstructured":"ClinicalTrials.gov, 2021f. Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01864655\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib85","unstructured":"ClinicalTrials.gov, {C}2020o{C}. A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease (GREEN MEMORY)."},{"key":"10.1016\/j.arr.2021.101496_bib86","unstructured":"ClinicalTrials.gov, 2020p. A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)."},{"key":"10.1016\/j.arr.2021.101496_bib87","unstructured":"ClinicalTrials.gov, {C}2020i{C}. Randomized I\/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04570644\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib88","unstructured":"ClinicalTrials.gov, 2020j. Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (COGNITE)."},{"key":"10.1016\/j.arr.2021.101496_bib89","unstructured":"ClinicalTrials.gov, 2020g. Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02002819\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib90","unstructured":"ClinicalTrials.gov, {C}2020h{C}. Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention ((PENSA)) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03978052\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib91","unstructured":"ClinicalTrials.gov, {C}2020m{C}. A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). (CREAD) \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT02670083\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib92","unstructured":"ClinicalTrials.gov, 2020n. A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03560245\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib93","unstructured":"ClinicalTrials.gov, {C}2020k{C}. Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00795418\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib94","unstructured":"ClinicalTrials.gov, 2020l. Seizure Activity in Alzheimer's Disease \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01554683\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib95","unstructured":"ClinicalTrials.gov, {C}2020s{C}. To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01023685\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib96","unstructured":"ClinicalTrials.gov, 2020t. Treating Hyperexcitability in AD With Levetiracetam \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03875638\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib97","unstructured":"ClinicalTrials.gov, {C}2021g{C}. Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (HOPE4MCI) \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03486938\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib98","unstructured":"ClinicalTrials.gov, {C}2014b{C}. Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01661673\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib99","unstructured":"ClinicalTrials.gov, {C}2020q{C}. Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03522129\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib100","unstructured":"ClinicalTrials.gov, 2020r. A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03507790\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib101","unstructured":"ClinicalTrials.gov, {C}2021c{C}. Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00955409\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib102","unstructured":"ClinicalTrials.gov, 2021d. Network-Level Mechanisms for Preclinical Alzheimer's Disease Development \u3008https:\/\/wiiww.clinicaltrials.gov\/ct2\/show\/NCT03461861\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib103","unstructured":"ClinicalTrials.gov, 2014a. Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01238991\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib104","unstructured":"ClinicalTrials.gov, 2021a. AHEAD 3\u201345 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib105","unstructured":"ClinicalTrials.gov, 2021b. A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640077\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib106","unstructured":"ClinicalTrials.gov, 2013. Alzheimer's Disease Acitretin Medication (ADAM) \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009\u2013011881-27\/DE\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib107","unstructured":"ClinicalTrials.gov, 2015. Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01485302\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib108","unstructured":"ClinicalTrials.gov, 2016. A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00960531\u3009."},{"key":"10.1016\/j.arr.2021.101496_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134750","article-title":"Optical coherence tomography in Alzheimer\u2019s disease: a meta-analysis","volume":"10","author":"Coppola","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib110","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib111","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuron.2010.05.014","article-title":"Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease","volume":"66","author":"Cortes-Canteli","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1523\/JNEUROSCI.2699-07.2008","article-title":"p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels through phosphatidylinositol 4,5-bisphosphate","volume":"28","author":"Coulson","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib113","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib114","doi-asserted-by":"crossref","unstructured":"Crary, J.F., Trojanowski, J.Q., Schneider, J.A., Abisambra, J.F., Abner, E.L., Alafuzoff, I., Arnold, S.E., Attems, J., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., Gearing, M., Grinberg, L.T., Hof, P.R., Hyman, B.T., Jellinger, K., Jicha, G.A., Kovacs, G.G., Knopman, D.S., Kofler, J., Kukull, W.A., Mackenzie, I.R., Masliah, E., McKee, A., Montine, T.J., Murray, M.E., Neltner, J.H., Santa-Maria, I., Seeley, W.W., Serrano-Pozo, A., Shelanski, M.L., Stein, T., Takao, M., Thal, D.R., Toledo, J.B., Troncoso, J.C., Vonsattel, J.P., White, C.L., {C}3rd{C}, Wisniewski, T., Woltjer, R.L., Yamada, M., Nelson, P.T., 2014. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766.","DOI":"10.1007\/s00401-014-1349-0"},{"key":"10.1016\/j.arr.2021.101496_bib115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-141872","article-title":"Influence of the APOE epsilon4 allele and mild cognitive impairment diagnosis in the disruption of the MEG resting state functional connectivity in sources space","volume":"44","author":"Cuesta","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib116","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.neurobiolaging.2005.10.016","article-title":"Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages","volume":"27","author":"Cullen","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib117","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0197-4580(96)00170-4","article-title":"Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib118","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib119","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40942-016-0049-4","article-title":"The role of optical coherence tomography in Alzheimer\u2019s disease","volume":"2","author":"Cunha","year":"2016","journal-title":"Int. J. Retin. Vitr."},{"key":"10.1016\/j.arr.2021.101496_bib121","series-title":"Bradley\u2019s Neurology in Clinical Practice E-Book","author":"Daroff","year":"2015"},{"key":"10.1016\/j.arr.2021.101496_bib122","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-3458.2007.00005.x","article-title":"Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug","volume":"13","author":"De Smedt","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.arr.2021.101496_bib124","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","article-title":"RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain","volume":"9","author":"Deane","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2021.101496_bib125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14737175.2016.1200972","article-title":"Targeting neuroinflammation in Alzheimer\u2019s disease: evidence for NSAIDs and novel therapeutics","volume":"17","author":"Deardorff","year":"2017","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.arr.2021.101496_bib126","unstructured":"Deepak, A., 2019. ABvac40. Alzheimer\u2019s News Today."},{"key":"10.1016\/j.arr.2021.101496_bib127","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0197-4580(93)90096-T","article-title":"Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians","volume":"14","author":"Delaere","year":"1993","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2020.104090","article-title":"On the impact of age, gender and educational level on cognitive function in Alzheimer\u2019s disease: a quantitative approach","volume":"89","author":"Delpak","year":"2020","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.arr.2021.101496_bib129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JAD-121501","article-title":"Blood transcriptomic biomarkers of Alzheimer\u2019s disease patients treated with EHT 0202","volume":"34","author":"D\u00e9sir\u00e9","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib130","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.neuropsychologia.2007.11.030","article-title":"Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies","volume":"46","author":"Dickerson","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.arr.2021.101496_bib131","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1523\/JNEUROSCI.2849-20.2021","article-title":"G-Protein-gated inwardly rectifying potassium (Kir3\/GIRK) channels govern synaptic plasticity that supports hippocampal-dependent cognitive functions in male mice","volume":"41","author":"Djebari","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103090","article-title":"The reelin receptors apolipoprotein E receptor 2 (ApoER2) and VLDL receptor","volume":"19","author":"Dlugosz","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.659817","article-title":"Predicting dementia with prefrontal electroencephalography and event-related potential","volume":"13","author":"Doan","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib134","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40262-012-0005-x","article-title":"A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects","volume":"51","author":"Dockens","year":"2012","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib136","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101496_bib137","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101496_bib138","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer\u2019s disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib139","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP","volume":"56","author":"Doran","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib140","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fneur.2017.00701","article-title":"Optical coherence tomography in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"8","author":"Doustar","year":"2017","journal-title":"Front Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib141","first-page":"2581","article-title":"Sex differences in the genetic predictors of Alzheimer's pathology","volume":"142","author":"Dumitrescu","year":"2019"},{"key":"10.1016\/j.arr.2021.101496_bib142","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/156720507783018190","article-title":"Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons","volume":"4","author":"Echeverria","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2021.101496_bib143","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnagi.2019.00146","article-title":"Modifiable risk factors for Alzheimer\u2019s disease","volume":"11","author":"Edwards Iii","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib144","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101496_bib145","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101496_bib146","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-019-0520-1","article-title":"Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer\u2019s disease","volume":"11","author":"Egan","year":"2019","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib147","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-190507","article-title":"Developing effective Alzheimer\u2019s disease therapies: clinical experience and future girections","volume":"71","author":"Elmaleh","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib148","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib149","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.23748","article-title":"Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls","volume":"73","author":"Esparza","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer\u2019s disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib151","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of bryostatin in the treatment of moderately severe to severe Alzheimer\u2019s disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib152","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101496_bib153","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","article-title":"Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology","volume":"85","author":"Fenili","year":"2007","journal-title":"J. Mol. Med (Berl. )"},{"key":"10.1016\/j.arr.2021.101496_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.690372","article-title":"Cholesterol and Alzheimer\u2019s disease; from risk genes to pathological effects","volume":"13","author":"Feringa","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib155","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/jnc.13687","article-title":"Mechanisms of homeostatic plasticity in the excitatory synapse","volume":"139","author":"Fernandes","year":"2016","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib156","doi-asserted-by":"crossref","first-page":"31043","DOI":"10.1074\/jbc.M114.581165","article-title":"Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid \u03b2-peptides (A\u03b2) by \u03b3-secretase to increase 42-to-40-residue A\u03b2","volume":"289","author":"Fernandez","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101496_bib157","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3233\/JAD-160886","article-title":"Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer\u2019s disease","volume":"56","author":"Ferrari","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib158","first-page":"169","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib159","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/gerona\/glaa200","article-title":"The ApoE locus and COVID-19: are we going where we have been?","volume":"76","author":"Finch","year":"2021","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"key":"10.1016\/j.arr.2021.101496_bib160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0197-4580(99)00053-6","article-title":"The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms","volume":"20","author":"Finch","year":"1999","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib161","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/M19-3887","article-title":"Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia","volume":"172","author":"Fink","year":"2020","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.arr.2021.101496_bib162","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nrl.2015.03.012","article-title":"Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein","volume":"33","author":"Folch","year":"2018","journal-title":"Neurologia"},{"key":"10.1016\/j.arr.2021.101496_bib163","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41598-020-59869-5","article-title":"Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E epsilon4 genotype","volume":"10","author":"Friedberg","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib164","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fncel.2020.00050","article-title":"Hebbian and homeostatic synaptic plasticity-do alterations of one reflect enhancement of the other?","volume":"14","author":"Galanis","year":"2020","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib165","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1523\/JNEUROSCI.1820-20.2021","article-title":"Amyloid-beta mediates homeostatic synaptic plasticity","volume":"41","author":"Galanis","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib166","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","article-title":"Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals","volume":"21","author":"Galasko","year":"2007","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101496_bib167","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fnins.2019.00556","article-title":"A crosstalk between brain cholesterol oxidation and glucose metabolism in Alzheimer\u2019s disease","volume":"13","author":"Gamba","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0194599812446282","article-title":"Central presbycusis: an emerging view","volume":"147","author":"Gates","year":"2012","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.arr.2021.101496_bib169","first-page":"342","article-title":"Complex regulation of \u03b3-secretase: from obligatory to modulatory subunits","volume":"6","author":"Gertsik","year":"2014","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib170","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009004","article-title":"The prion-like phenomenon in Alzheimer\u2019s disease: evidence of pathology transmission in humans","volume":"16","author":"Gomez-Gutierrez","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.arr.2021.101496_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20082037","article-title":"The role of ApoE in HCV infection and comorbidity","volume":"20","author":"Gong","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib173","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fnagi.2018.00101","article-title":"Theta-gamma coupling and working memory in Alzheimer\u2019s dementia and mild cognitive impairment","volume":"10","author":"Goodman","year":"2018","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib174","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib175","first-page":"134","article-title":"Hippocampal oscillatory activity in Alzheimer\u2019s disease: toward the identification of early biomarkers?","volume":"4","author":"Goutagny","year":"2013","journal-title":"Aging Dis."},{"key":"10.1016\/j.arr.2021.101496_bib176","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101496_bib177","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3233\/JAD-200610","article-title":"Anticoagulants for treatment of Alzheimer\u2019s disease","volume":"77","author":"Grossmann","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib178","first-page":"20","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib179","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1074\/jbc.M806508200","article-title":"{beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+\/calmodulin-dependent protein kinase II synaptic distribution","volume":"284","author":"Gu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101496_bib180","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fnagi.2018.00437","article-title":"Executive functions in Alzheimer disease: a systematic review","volume":"10","author":"Guarino","year":"2018","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib181","article-title":"Sex differences in Alzheimer\u2019s disease: insights from the multiomics landscape","author":"Guo","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib182","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tins.2018.07.001","article-title":"Microbes and Alzheimer\u2019s disease: new findings call for a paradigm change","volume":"41","author":"Haas","year":"2018","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib183","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1073\/pnas.1615613114","article-title":"Systematic development of small molecules to inhibit specific microscopic steps of Abeta42 aggregation in Alzheimer\u2019s disease","volume":"114","author":"Habchi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib184","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-beta pathway in Alzheimer\u2019s disease","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib185","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/jphp.13132","article-title":"Advancements in nanotherapeutics for Alzheimer\u2019s disease: current perspectives","volume":"71","author":"Harilal","year":"2019","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib186","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1460-9568.2009.07052.x","article-title":"Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"Hawkes","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib187","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fnagi.2019.00324","article-title":"Perturbations of ubiquitin-proteasome-mediated proteolysis in aging and Alzheimer\u2019s disease","volume":"11","author":"Hegde","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib188","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5924","article-title":"Small-molecule sequestration of amyloid-beta as a drug discovery strategy for Alzheimer\u2019s disease","volume":"6","author":"Heller","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.arr.2021.101496_bib189","first-page":"91","article-title":"Methodological aspects of the phase II study AFF006 evaluating amyloid-beta -targeting vaccine AFFITOPE\u00ae AD02 in early Alzheimer\u2019s disease - prospective use of novel composite scales","volume":"2","author":"Hendrix","year":"2015","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib190","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2021.101496_bib191","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib192","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101496_bib193","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2021.101496_bib194","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/WAD.0000000000000134","article-title":"Epileptic seizures in Alzheimer disease: a review","volume":"30","author":"Horvath","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101496_bib195","doi-asserted-by":"crossref","first-page":"387","DOI":"10.12688\/f1000research.18671.2","article-title":"Sex differences in gene expression patterns associated with the APOE4 allele","volume":"8","author":"Hsu","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.arr.2021.101496_bib196","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jcph.393","article-title":"Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer\u2019s disease","volume":"55","author":"Hu","year":"2015","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib197","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-021-24220-7","article-title":"Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer\u2019s disease","volume":"12","author":"Hu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2021.101496_bib198","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.12.044","article-title":"ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Abeta secretion","volume":"168","author":"Huang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.arr.2021.101496_bib200","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.630502","article-title":"APOE and Alzheimer\u2019s Disease: From Lipid Transport to Physiopathology and Therapeutics","volume":"15","author":"Husain","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib201","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fphar.2020.00261","article-title":"Pharmacotherapy of Alzheimer\u2019s disease: seeking clarity in a time of uncertainty","volume":"11","author":"Husna Ibrahim","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib202","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2021.101496_bib203","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WAD.0b013e3182622ace","article-title":"Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects","volume":"27","author":"Imbimbo","year":"2013","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101496_bib204","doi-asserted-by":"crossref","first-page":"P352","DOI":"10.1016\/j.jalz.2016.06.665","article-title":"O4-08-06: safety, pharmacokinetics (pk), and Florbetapir F-18 positron emission tomography (PET) after multiple dose administration of ly3002813, a \u03b2-amyloid plaque-specific antibody, in Alzheimer\u2019s disease (AD)","volume":"12","author":"Irizarry","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib205","doi-asserted-by":"crossref","first-page":"P1622","DOI":"10.1016\/j.jalz.2018.07.212","article-title":"P4-388: Trailblazer-alz (nct03367403): a phase 2 disease-modification combination therapy trial targeting multiple mechanisms of action along the amyloid pathway","volume":"14","author":"Irizarry","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib206","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib207","article-title":"Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib208","article-title":"Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib209","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fnins.2018.00125","article-title":"Impact of aging on the auditory system and related cognitive functions: a narrative review","volume":"12","author":"Jayakody","year":"2018","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107808","article-title":"Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system","volume":"223","author":"Jeremic","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib212","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib214","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2013.12.016","article-title":"Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner","volume":"64","author":"Johnson","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101496_bib215","doi-asserted-by":"crossref","first-page":"43701","DOI":"10.1038\/srep43701","article-title":"Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome","volume":"7","author":"Johnson","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib216","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20180653","article-title":"Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau","volume":"215","author":"Kang","year":"2018","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.arr.2021.101496_bib217","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1212\/WNL.0b013e3182896e79","article-title":"Infectious burden and cognitive function: the Northern Manhattan Study","volume":"80","author":"Katan","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib218","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-017-0411-2","article-title":"Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease","volume":"5","author":"Kelly","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2021.101496_bib219","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.arr.2021.101496_bib220","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib221","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14728222.2020.1790530","article-title":"Deciphering Alzheimer\u2019s disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis","volume":"24","author":"Khoury","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.arr.2021.101496_bib222","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/jnnp-2015-311486","article-title":"IVIG treatment of mild cognitive impairment due to Alzheimer\u2019s disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia","volume":"88","author":"Kile","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib223","doi-asserted-by":"crossref","first-page":"767","DOI":"10.14348\/molcells.2014.0248","article-title":"Apolipoprotein E in synaptic plasticity and Alzheimer\u2019s disease: potential cellular and molecular mechanisms","volume":"37","author":"Kim","year":"2014","journal-title":"Mol. Cells"},{"key":"10.1016\/j.arr.2021.101496_bib224","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1471-4159.2002.01016.x","article-title":"Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus","volume":"82","author":"Kinoshita","year":"2002","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib226","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0197-0186(02)00050-5","article-title":"Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets","volume":"41","author":"Klein","year":"2002","journal-title":"Neurochem Int"},{"key":"10.1016\/j.arr.2021.101496_bib227","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2020.00754","article-title":"The important interface between apolipoprotein E and neuroinflammation in Alzheimer\u2019s disease","volume":"11","author":"Kloske","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.arr.2021.101496_bib228","article-title":"Neurologija za studente medicine","author":"Kostic","year":"2018","journal-title":"Med. Fak. Beogr."},{"key":"10.1016\/j.arr.2021.101496_bib229","article-title":"Genetic and regulatory architecture of Alzheimer's disease in the APOE region","volume":"12","author":"Kulminski","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnagi.2011.00007","article-title":"Long-term potentiation at CA3-CA1 hippocampal synapses with special emphasis on aging, disease, and stress","volume":"3","author":"Kumar","year":"2011","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib231","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.cell.2014.07.035","article-title":"Reelin signaling specifies the molecular identity of the pyramidal neuron distal dendritic compartment","volume":"158","author":"Kupferman","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.arr.2021.101496_bib232","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1523\/JNEUROSCI.0157-10.2010","article-title":"Abeta-mediated NMDA receptor endocytosis in Alzheimer\u2019s disease involves ubiquitination of the tyrosine phosphatase STEP61","volume":"30","author":"Kurup","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib233","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer\u2019s disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.arr.2021.101496_bib234","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jval.2015.03.1787","article-title":"Quality of life and utility measurement in a large clinical trial sample of patients with mild to moderate Alzheimer\u2019s disease: determinants and level of changes observed","volume":"18","author":"Lacey","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.arr.2021.101496_bib235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2(40) vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib236","first-page":"537","article-title":"Marine derived bioactive compounds for treatment of Alzheimer\u2019s disease","volume":"10","author":"Lakshmi","year":"2018","journal-title":"Front Biosci. (Elite Ed. )"},{"key":"10.1016\/j.arr.2021.101496_bib237","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2147\/NDT.S203103","article-title":"What are the links between hypoxia and Alzheimer\u2019s disease?","volume":"15","author":"Lall","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.arr.2021.101496_bib238","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm.4330","article-title":"Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer\u2019s disease","volume":"23","author":"Lam","year":"2017","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2021.101496_bib239","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","article-title":"Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study","volume":"36","author":"Landen","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2021.101496_bib240","first-page":"393","article-title":"Ponezumab in mild-to-moderate Alzheimer\u2019s disease: randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib241","first-page":"339","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib242","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2011-102148","article-title":"Epileptic seizures in Alzheimer\u2019s disease: another fine MESS?","volume":"25","author":"Larner","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib243","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jama.300.9.1027","article-title":"Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial","volume":"300","author":"Lautenschlager","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101496_bib244","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2020.04.040","article-title":"Retinal biomarkers of Alzheimer disease","volume":"218","author":"Lee","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.arr.2021.101496_bib245","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1476-5381.2009.00463.x","article-title":"Levetiracetam inhibits glutamate transmission through presynaptic P\/Q-type calcium channels on the granule cells of the dentate gyrus","volume":"158","author":"Lee","year":"2009","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib246","article-title":"Redefining transcriptional regulation of the APOE gene and its association with Alzheimer's disease","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib247","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20592","article-title":"Abeta42 immunization in Alzheimer\u2019s disease generates Abeta N-terminal antibodies","volume":"58","author":"Lee","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib248","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm1096-1146","article-title":"The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology","volume":"2","author":"Lemere","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2021.101496_bib249","first-page":"141","article-title":"NPT088 reduces both amyloid-beta and tau pathologies in transgenic mice","volume":"2","author":"Levenson","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib250","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1073\/pnas.1613700114","article-title":"Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimer\u2019s disease","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib251","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jnc.15007","article-title":"A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer\u2019s brain","volume":"154","author":"Li","year":"2020","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib252","first-page":"5","article-title":"How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity?","volume":"4","author":"Li","year":"2010","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib253","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cpdd.14","article-title":"Pharmacokinetic profile of orally administered Scyllo-Inositol (Elnd005) in plasma, cerebrospinal fluid and brain, and corresponding effect on amyloid-beta in healthy subjects","volume":"2","author":"Liang","year":"2013","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.arr.2021.101496_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib255","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib256","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-142508","article-title":"Cognitive impairment precedes and predicts functional impairment in mild Alzheimer\u2019s disease","volume":"47","author":"Liu-Seifert","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib257","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fnmol.2019.00198","article-title":"Secreted amyloid precursor protein-alpha promotes arc protein synthesis in hippocampal neurons","volume":"12","author":"Livingstone","year":"2019","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib258","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2017.09.008","article-title":"Targeting demyelination via \u03b1-secretases promoting sAPP\u03b1 release to enhance remyelination in central nervous system","volume":"109","author":"Llufriu-Dab\u00e9n","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101496_bib259","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib260","first-page":"242","article-title":"The Alzheimer\u2019s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer\u2019s disease","volume":"4","author":"Lopez Lopez","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib261","first-page":"216","article-title":"The Alzheimer\u2019s prevention initiative generation program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease","volume":"5","author":"Lopez Lopez","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib262","first-page":"41","article-title":"D-pinitol, a highly valuable product from carob pods: Health-promoting effects and metabolic pathways of this natural super-food ingredient and its derivatives","volume":"3","author":"Lopez-Sanchez","year":"2018","journal-title":"Aims Agric. Food"},{"key":"10.1016\/j.arr.2021.101496_bib263","doi-asserted-by":"crossref","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","article-title":"Elenbecestat, e2609, a BACE inhibitor: results from a phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer's disease","volume":"14","author":"Lynch","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib264","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","article-title":"scyllo-Inositol, preclinical, and clinical data for Alzheimer\u2019s disease","volume":"64","author":"Ma","year":"2012","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib265","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101372","article-title":"Neuronal excitation\/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology","volume":"69","author":"Maestu","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2021.101496_bib266","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neuron.2012.11.020","article-title":"Apolipoprotein e sets the stage: response to injury triggers neuropathology","volume":"76","author":"Mahley","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2011.05.2274","article-title":"Development of AFFITOPE Alzheimer vaccines: Results of phase I studies with AD01 and AD02","volume":"7","author":"Mandler","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib268","article-title":"Vaccination against \u03b2-Amyloid as a strategy for the prevention of Alzheimer\u2019s disease","volume":"9","author":"Mantile","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.arr.2021.101496_bib269","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1172\/JCI65401","article-title":"Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer\u2019s disease","volume":"123","author":"Marcello","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.arr.2021.101496_bib270","article-title":"Promising results from Alzheimer\u2019s disease passive immunotherapy support the development of a preventive vaccine","volume":"2019","author":"Marciani","year":"2019","journal-title":"Res. (Wash. D. C. )"},{"key":"10.1016\/j.arr.2021.101496_bib271","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.arr.2021.101496_bib272","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134385","article-title":"Amyloid-beta(25-35) modulates the expression of GirK and KCNQ channel genes in the hippocampus","volume":"10","author":"Mayordomo-Cava","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib273","article-title":"Impairments of synaptic plasticity induction threshold and network oscillatory activity in the hippocampus underlie memory deficits in a non-transgenic mouse model of amyloidosis","volume":"9","author":"Mayordomo-Cava","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.arr.2021.101496_bib274","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib275","unstructured":"McLaurin, J., 2010. Methods of preventing, treating and diagnosing disorders of protein aggregation, European patent EU 2153829A1."},{"key":"10.1016\/j.arr.2021.101496_bib276","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2017.09.027","article-title":"Cortical beta-amyloid burden, gray matter, and memory in adults at varying APOE epsilon4 risk for Alzheimer\u2019s disease","volume":"61","author":"Mecca","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib277","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244180","article-title":"Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment","volume":"16","author":"Meghdadi","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101496_bib278","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/acschemneuro.1c00047","article-title":"Small-molecule targeted Abeta42 aggregate degradation: negatively charged small molecules are more promising than the neutral ones","volume":"12","author":"Mei","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib279","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","article-title":"Recent developments of small molecule \u03b3-secretase modulators for Alzheimer\u2019s disease","volume":"11","author":"Mekala","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.arr.2021.101496_bib280","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1073\/pnas.95.21.12683","article-title":"Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice","volume":"95","author":"Meziane","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib281","doi-asserted-by":"crossref","first-page":"228","DOI":"10.14283\/jpad.2019.37","article-title":"Randomized, placebo controlled trial of NPT088, a phage-derived, amyloid-targeted treatment for Alzheimer\u2019s disease","volume":"6","author":"Michelson","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib282","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2021.101496_bib283","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/0956797611400914","article-title":"Changes in EEG cross-frequency coupling during cognitive behavioral therapy for social anxiety disorder","volume":"22","author":"Miskovic","year":"2011","journal-title":"Psychol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib284","article-title":"Exploring the genetic relationship between hearing impairment and Alzheimer's disease","volume":"12","author":"Mitchell","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng0996-55","article-title":"Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides","volume":"14","author":"Miyata","year":"1996","journal-title":"Nat. Genet"},{"key":"10.1016\/j.arr.2021.101496_bib286","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5414\/CP201816","article-title":"Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer\u2019s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"51","author":"Miyoshi","year":"2013","journal-title":"Int J. Clin. Pharm. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib287","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0022-510X(92)90047-O","article-title":"Neuropathological background of twenty-seven centenarian brains","volume":"108","author":"Mizutani","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib288","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2021.101496_bib289","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/jnc.12332","article-title":"Antibodies bound to Abeta oligomers potentiate the neurotoxicity of Abeta by activating microglia","volume":"126","author":"Morkuniene","year":"2013","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib290","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.46.3.707","article-title":"Cerebral amyloid deposition and diffuse plaques in \u201cnormal\u201d aging: evidence for presymptomatic and very mild Alzheimer\u2019s disease","volume":"46","author":"Morris","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib291","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.3233\/JAD-190744","article-title":"Current and emerging pharmacological targets for the treatment of Alzheimer\u2019s disease","volume":"72","author":"Morsy","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib292","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0197-4580(01)00287-1","article-title":"Interleukin-1, neuroinflammation, and Alzheimer\u2019s disease","volume":"22","author":"Mrak","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib293","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib294","article-title":"Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease","author":"Musiek","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13024-019-0324-6","article-title":"Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer\u2019s disease","volume":"14","author":"Najm","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101496_bib296","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000436935.47657.78","article-title":"Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults","volume":"81","author":"Nation","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib297","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fncel.2013.00117","article-title":"Amyloid-beta induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse","volume":"7","author":"Nava-Mesa","year":"2013","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib298","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fncel.2014.00167","article-title":"GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer\u2019s disease","volume":"8","author":"Nava-Mesa","year":"2014","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib299","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-170161","article-title":"Bryostatin effects on cognitive function and PKC\u025b in Alzheimer\u2019s disease phase IIa and expanded access trials","volume":"58","author":"Nelson","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib300","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2021.101496_bib301","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2303","article-title":"Synaptic plasticity, memory and the hippocampus: a neural network approach to causality","volume":"9","author":"Neves","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-014-1347-2","article-title":"The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes","volume":"129","author":"Nhan","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101496_bib303","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2021.101496_bib304","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1528-1167.2009.02135.x","article-title":"Foramen ovale electrodes in the preoperative evaluation of temporal lobe epilepsy in children","volume":"50","author":"Nilsson","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.arr.2021.101496_bib305","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1167\/iovs.08-1849","article-title":"Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease","volume":"49","author":"Ning","year":"2008","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib306","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib307","doi-asserted-by":"crossref","unstructured":"Novartis, 2019. Novartis Q3 and 9M 2019 Condensed Interim Financial Report.","DOI":"10.1002\/nba.30647"},{"key":"10.1016\/j.arr.2021.101496_bib308","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41467-017-01444-0","article-title":"Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer\u2019s disease-like pathology","volume":"8","author":"Nuriel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2021.101496_bib309","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt238","article-title":"Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease","volume":"6","author":"Nygaard","year":"2014","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib310","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13041-021-00803-9","article-title":"APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer\u2019s disease and age-matched non-demented brains","volume":"14","author":"Ojo","year":"2021","journal-title":"Mol. Brain"},{"key":"10.1016\/j.arr.2021.101496_bib311","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","article-title":"A brief overview of tauopathy: causes, consequences, and therapeutic strategies","volume":"38","author":"Orr","year":"2017","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib312","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib313","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib314","article-title":"Clinical trials in Alzheimer\u2019s disease: a hurdle in the path of remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib315","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archneurol.2009.15","article-title":"Epilepsy and cognitive impairments in Alzheimer disease","volume":"66","author":"Palop","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib316","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-beta-induced neuronal dysfunction in Alzheimer\u2019s disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib317","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib318","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1523\/JNEUROSCI.2829-05.2005","article-title":"Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice","volume":"25","author":"Palop","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib319","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101496_bib320","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib321","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tins.2007.02.001","article-title":"New vistas for alpha-frequency band oscillations","volume":"30","author":"Palva","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib322","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737175.2014.945522","article-title":"Efficacy and safety studies of gantenerumab in patients with Alzheimer\u2019s disease","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.arr.2021.101496_bib323","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14712598.2018.1389885","article-title":"The potential of solanezumab and gantenerumab to prevent Alzheimer\u2019s disease in people with inherited mutations that cause its early onset","volume":"18","author":"Panza","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib324","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib325","doi-asserted-by":"crossref","DOI":"10.1177\/2040622318811000","article-title":"Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life","volume":"10","author":"Panza","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.arr.2021.101496_bib326","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.etap.2014.01.008","article-title":"Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase\/Akt pathway","volume":"37","author":"Park","year":"2014","journal-title":"Environ. Toxicol. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib327","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40364-020-00258-5","article-title":"Plasma contact factors as novel biomarkers for diagnosing Alzheimer\u2019s disease","volume":"9","author":"Park","year":"2021","journal-title":"Biomark. Res"},{"key":"10.1016\/j.arr.2021.101496_bib328","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","article-title":"Amyloid-\u03b2 and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer\u2019s disease","volume":"22","author":"Pascoal","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib329","unstructured":"Pasinetti, G.M., 2006. Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system, United States patent US 2006\/0111450A1."},{"key":"10.1016\/j.arr.2021.101496_bib330","unstructured":"Pasinetti, G.M., 2013. Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system, United States patent US 2013\/0123370A1."},{"key":"10.1016\/j.arr.2021.101496_bib331","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib332","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.phrs.2018.01.018","article-title":"Synaptic plasticity modulation by circulating peptides and metaplasticity: involvement in Alzheimer\u2019s disease","volume":"130","author":"Peineau","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.arr.2021.101496_bib333","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.3233\/JAD-180631","article-title":"Air pollution and dementia: a systematic review","volume":"70","author":"Peters","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib334","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn.2018.13","article-title":"Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics","volume":"19","author":"Petersen","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib335","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JAD-150282","article-title":"sA\u03b2PP\u03b1 is a potent endogenous inhibitor of BACE1","volume":"47","author":"Peters-Libeu","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib336","doi-asserted-by":"crossref","first-page":"58","DOI":"10.32607\/20758251-2016-8-1-58-73","article-title":"Brain cholesterol metabolism and its defects: linkage to neurodegenerative diseases and synaptic dysfunction","volume":"8","author":"Petrov","year":"2016","journal-title":"Acta Nat."},{"key":"10.1016\/j.arr.2021.101496_bib337","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104823","article-title":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","volume":"139","author":"Petrushina","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101496_bib338","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2019.11.015","article-title":"A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers","volume":"42","author":"Portron","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib339","doi-asserted-by":"crossref","first-page":"E6640","DOI":"10.1073\/pnas.1801612115","article-title":"Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH","volume":"115","author":"Prasad","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib340","first-page":"199","volume":"24","author":"Przewozny","year":"2015"},{"key":"10.1016\/j.arr.2021.101496_bib341","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","article-title":"Hippocampal hyperactivation associated with cortical thinning in Alzheimer\u2019s disease signature regions in non-demented elderly adults","volume":"31","author":"Putcha","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib342","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3758\/s13415-013-0238-7","article-title":"EEG theta\/beta ratio as a potential biomarker for attentional control and resilience against deleterious effects of stress on attention","volume":"14","author":"Putman","year":"2014","journal-title":"Cogn. Affect Behav. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib343","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41598-020-80164-w","article-title":"The Abeta(1-38) peptide is a negative regulator of the Abeta(1-42) peptide implicated in Alzheimer disease progression","volume":"11","author":"Quartey","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib344","doi-asserted-by":"crossref","first-page":"91236","DOI":"10.1155\/2007\/91236","article-title":"Role of apolipoprotein E in anxiety","volume":"2007","author":"Raber","year":"2007","journal-title":"Neural Plast."},{"key":"10.1016\/j.arr.2021.101496_bib345","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40263-020-00740-6","article-title":"Alzheimer\u2019s disease in down syndrome: progress in the design and conduct of drug prevention trials","volume":"34","author":"Rafii","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2021.101496_bib346","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib347","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jalz.2018.12.010","article-title":"Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr)","volume":"15","author":"Ramirez Aguilar","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib348","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1750-1326-7-37","article-title":"Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice","volume":"7","author":"Rasool","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101496_bib349","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1194\/jlr.R075408","article-title":"The role of APOE on lipid homeostasis and inflammation in normal brains","volume":"58","author":"Rebeck","year":"2017","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.arr.2021.101496_bib350","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1474-9726.2008.00434.x","article-title":"Selective induction of calcineurin activity and signaling by oligomeric amyloid beta","volume":"7","author":"Reese","year":"2008","journal-title":"Aging Cell"},{"key":"10.1016\/j.arr.2021.101496_bib351","unstructured":"Register, E.C.T., 2018. A Phase I\/II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity, and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease."},{"key":"10.1016\/j.arr.2021.101496_bib352","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000512","article-title":"Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference?","volume":"6","author":"Reitz","year":"2020","journal-title":"Neurol. Genet"},{"key":"10.1016\/j.arr.2021.101496_bib353","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib354","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib355","first-page":"23","article-title":"Peptides as potential therapeutics for Alzheimer\u2019s disease","author":"Ribari\u010d","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2021.101496_bib356","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib357","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29595","article-title":"Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels","volume":"6","author":"Robert","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.arr.2021.101496_bib358","doi-asserted-by":"crossref","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 Reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study","author":"Ross","year":"2013","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2021.101496_bib359","series-title":"The Neurobiology of Learning and Memory","author":"Rudy","year":"2020"},{"key":"10.1016\/j.arr.2021.101496_bib360","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1523\/JNEUROSCI.1409-18.2018","article-title":"Synaptotoxicity in Alzheimer\u2019s disease involved a dysregulation of actin cytoskeleton dynamics through cofilin 1 phosphorylation","volume":"38","author":"Rush","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib361","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(00)80563-2","article-title":"BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses","volume":"21","author":"Rutherford","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib362","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0b013e318204b550","article-title":"PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease","volume":"25","author":"Sabbagh","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101496_bib363","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2015.10.003","article-title":"The alpha secretase ADAM10: a metalloprotease with multiple functions in the brain","volume":"135","author":"Saftig","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.arr.2021.101496_bib364","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib365","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101496_bib366","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2021.101496_bib367","first-page":"157","article-title":"Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab","volume":"1","author":"Samtani","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib368","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib369","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11101-020-09677-6","article-title":"d-Pinitol: a cyclitol with versatile biological and pharmacological activities","volume":"20","author":"Sanchez-Hidalgo","year":"2021","journal-title":"Phytochem. Rev."},{"key":"10.1016\/j.arr.2021.101496_bib370","doi-asserted-by":"crossref","first-page":"14658","DOI":"10.1038\/s41598-017-15306-8","article-title":"Activation of G-protein-gated inwardly rectifying potassium (Kir3\/GirK) channels rescues hippocampal functions in a mouse model of early amyloid-beta pathology","volume":"7","author":"Sanchez-Rodriguez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib371","first-page":"20","article-title":"Role of GirK channels in long-term potentiation of synaptic inhibition in an in vivo mouse model of early amyloid-beta pathology","author":"Sanchez-Rodriguez","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib372","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/jnc.14946","article-title":"Hippocampal long-term synaptic depression and memory deficits induced in early amyloidopathy are prevented by enhancing G-protein-gated inwardly rectifying potassium channel activity","volume":"153","author":"Sanchez-Rodriguez","year":"2020","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib373","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fnins.2019.00619","article-title":"The age-related central auditory processing disorder: silent impairment of the cognitive ear","volume":"13","author":"Sardone","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib374","first-page":"1","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib375","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fnagi.2015.00199","article-title":"The roles of lipid and glucose metabolism in modulation of beta-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease","volume":"7","author":"Sato","year":"2015","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib376","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.2009.1144","article-title":"Physical activity, diet, and risk of Alzheimer disease","volume":"302","author":"Scarmeas","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101496_bib377","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101496_bib378","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.11.056","article-title":"Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states","volume":"1197","author":"Schmid","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2021.101496_bib379","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41419-020-02776-4","article-title":"Altered mitochondrial dynamics and function in APOE4-expressing astrocytes","volume":"11","author":"Schmukler","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.arr.2021.101496_bib380","first-page":"103","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE\u00ae AD02 in patients with early Alzheimer\u2019s disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib381","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib382","first-page":"328","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib383","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer's disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib384","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib385","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.aay5188","article-title":"Early network dysfunction in Alzheimer's disease","volume":"365","author":"Selkoe","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.arr.2021.101496_bib386","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.arr.2021.101496_bib387","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13063-021-05404-4","article-title":"An investigation of levetiracetam in Alzheimer\u2019s disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study","volume":"22","author":"Sen","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.arr.2021.101496_bib388","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bpa.12004","article-title":"Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer\u2019s disease","volume":"23","author":"Sengillo","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.arr.2021.101496_bib389","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2021.101496_bib390","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-019-0227-7","article-title":"The microbiome: a target for Alzheimer disease?","volume":"29","author":"Seo","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.arr.2021.101496_bib391","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-200735","article-title":"Retinal optical coherence tomography metrics are unchanged in verubecestat Alzheimer\u2019s disease clinical trial but correlate with baseline regional brain atrophy","volume":"79","author":"Sergott","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib392","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101496_bib393","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2021.101496_bib394","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105408","article-title":"Sensorineural hearing loss may lead to dementia-related pathological changes in hippocampal neurons","volume":"156","author":"Shen","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101496_bib395","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/archneurol.2011.203","article-title":"Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies","volume":"68","author":"Shepardson","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib396","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneurol.2011.242","article-title":"Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations","volume":"68","author":"Shepardson","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib397","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101496_bib398","doi-asserted-by":"crossref","first-page":"21341","DOI":"10.1073\/pnas.0908193106","article-title":"Phase-dependent neuronal coding of objects in short-term memory","volume":"106","author":"Siegel","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib399","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jnc.14793","article-title":"Plasma kallikrein-kinin system contributes to peripheral inflammation in temporal lobe epilepsy","volume":"150","author":"Simoes","year":"2019","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib400","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41593-020-0599-5","article-title":"The multiplex model of the genetics of Alzheimer\u2019s disease","volume":"23","author":"Sims","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib401","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1523\/JNEUROSCI.1492-19.2019","article-title":"Tumor necrosis factor-\u03b1-mediated metaplastic inhibition of LTP Is constitutively engaged in an Alzheimer\u2019s disease model","volume":"39","author":"Singh","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib402","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0197-4580(95)02067-5","article-title":"Intraneuronal beta-amyloid immunoreactivity in the CNS","volume":"17","author":"Sparks","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib403","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","article-title":"Amyloid deposition is associated with impaired default network function in older persons without dementia","volume":"63","author":"Sperling","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib404","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib405","series-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2013"},{"key":"10.1016\/j.arr.2021.101496_bib406","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2014.08.014","article-title":"Storm before the quiet: neuronal hyperactivity and A\u03b2 in the presymptomatic stages of Alzheimer\u2019s disease","volume":"36","author":"Stargardt","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib407","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2021.4622","article-title":"The accelerated approval of aducanumab for treatment of patients with Alzheimer disease","author":"Steinbrook","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arr.2021.101496_bib408","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/nature04671","article-title":"Synaptic scaling mediated by glial TNF-alpha","volume":"440","author":"Stellwagen","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101496_bib409","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","article-title":"Cognitive reserve in ageing and Alzheimer\u2019s disease","volume":"11","author":"Stern","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JAD-150687","article-title":"A mitochondrial role of SV2a protein in aging and Alzheimer\u2019s disease: studies with levetiracetam","volume":"50","author":"Stockburger","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib411","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101318","article-title":"Therapy for Alzheimer\u2019s disease: missing targets and functional markers?","volume":"68","author":"Stoiljkovic","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2021.101496_bib412","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41593-018-0080-x","article-title":"Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer\u2019s disease","volume":"21","author":"Styr","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib413","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1523\/JNEUROSCI.5616-10.2011","article-title":"PSD-95 and PSD-93 play critical but distinct roles in synaptic scaling up and down","volume":"31","author":"Sun","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib414","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer\u2019s disease brain","author":"Sur","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.arr.2021.101496_bib415","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2183\/pjab.93.048","article-title":"The past, present, and future of disease-modifying therapies for Alzheimer\u2019s disease","volume":"93","author":"Suzuki","year":"2017","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib416","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib417","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40142-020-00182-y","article-title":"Alzheimer\u2019s disease genetics: review of novel loci associated with disease","volume":"8","author":"T\u00e1buas-Pereira","year":"2020","journal-title":"Curr. Genet Med Rep."},{"key":"10.1016\/j.arr.2021.101496_bib418","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1172\/JCI124853","article-title":"APOE4-mediated amyloid-beta pathology depends on its neuronal receptor LRP1","volume":"129","author":"Tachibana","year":"2019","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.arr.2021.101496_bib419","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-016-1547-z","article-title":"The role of APOE in cerebrovascular dysfunction","volume":"131","author":"Tai","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101496_bib420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173873","article-title":"Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer\u2019s disease: pathological mechanisms and therapeutic outlooks","volume":"895","author":"Tajbakhsh","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib421","doi-asserted-by":"crossref","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","article-title":"A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss","volume":"110","author":"Talantova","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib422","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10020122","article-title":"Enhancing \u03b1-secretase processing for Alzheimer\u2019s disease-a view on SFRP1","volume":"10","author":"Tang","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.arr.2021.101496_bib423","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib424","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/JMN:23:3:167","article-title":"ApoE-dependent plasticity in Alzheimer\u2019s disease","volume":"23","author":"Teter","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib425","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00292-004-0695-4","article-title":"Post-mortem diagnosis of Alzheimer\u2019s disease","volume":"26","author":"Thal","year":"2005","journal-title":"Pathologe"},{"key":"10.1016\/j.arr.2021.101496_bib426","article-title":"A review on advances of treatment modalities for Alzheimer\u2019s disease","volume":"276","author":"Thoe","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2021.101496_bib427","first-page":"202","article-title":"Profiling the dynamics of CSF and plasma A\u03b2 reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor","volume":"2","author":"Timmers","year":"2016"},{"key":"10.1016\/j.arr.2021.101496_bib428","first-page":"1437","article-title":"BACE1 Dynamics upon inhibition with a BACE inhibitor and correlation to downstream Alzheimer\u2019s disease markers in elderly healthy participants","volume":"56","author":"Timmers","year":"2017"},{"key":"10.1016\/j.arr.2021.101496_bib429","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib430","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib431","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40261-012-0006-4","article-title":"Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid A\u03b2 levels in healthy young men","volume":"32","author":"Tong","year":"2012","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.arr.2021.101496_bib432","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clinthera.2012.01.022","article-title":"Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral \u03b3-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers","volume":"34","author":"Tong","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib433","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2125.2012.04339.x","article-title":"A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the \u03b3-secretase inhibitor avagacestat","volume":"75","author":"Tong","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib434","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.124","article-title":"Stem cell therapy for Alzheimer\u2019s disease and related disorders: current status and future perspectives","volume":"47","author":"Tong","year":"2015","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.arr.2021.101496_bib435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239318","article-title":"Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer\u2019s disease","volume":"21","author":"Toniolo","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101496_bib436","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-444-54299-1.00001-7","article-title":"Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future","volume":"197","author":"de la Torre","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.arr.2021.101496_bib437","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1474-4422(16)30034-5","article-title":"Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down\u2019s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"15","author":"de la Torre","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib438","doi-asserted-by":"crossref","first-page":"20942","DOI":"10.1073\/pnas.0911331106","article-title":"Theta-gamma coupling increases during the learning of item-context associations","volume":"106","author":"Tort","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib439","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/187152709787847306","article-title":"Alternative Abeta immunotherapy approaches for Alzheimer\u2019s disease","volume":"8","author":"Town","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.arr.2021.101496_bib440","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.1523\/JNEUROSCI.2010-13.2013","article-title":"Dab1 is required for synaptic plasticity and associative learning","volume":"33","author":"Trotter","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib441","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/706768","article-title":"The exposome in human evolution: from dust to diesel","volume":"94","author":"Trumble","year":"2019","journal-title":"Q Rev. Biol."},{"key":"10.1016\/j.arr.2021.101496_bib442","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.14336\/AD.2020.0310","article-title":"Influence of BDNF genetic polymorphisms in the pathophysiology of aging-related diseases","volume":"11","author":"Urbina-Varela","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.arr.2021.101496_bib443","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2021.101496_bib444","doi-asserted-by":"crossref","first-page":"20058","DOI":"10.1038\/s41598-020-77023-z","article-title":"Interaction of neuropsychiatric symptoms with APOE epsilon4 and conversion to dementia in MCI patients in a Memory Clinic","volume":"10","author":"Valero","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib445","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib446","first-page":"75","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer\u2019s disease: amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib447","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial","volume":"76","author":"van Dyck","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib448","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther."},{"issue":"Suppl 1","key":"10.1016\/j.arr.2021.101496_bib449","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.metabol.2012.08.024","article-title":"Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention","volume":"62","author":"Vanitallie","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.arr.2021.101496_bib450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2021.101496_bib451","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2021.101496_bib452","doi-asserted-by":"crossref","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","article-title":"ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE\/Abeta association in physiological conditions","volume":"110","author":"Verghese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101496_bib453","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.cell.2012.02.046","article-title":"Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model","volume":"149","author":"Verret","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.arr.2021.101496_bib454","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1535-7511.2007.00165.x","article-title":"New roles for interleukin-1 beta in the mechanisms of epilepsy","volume":"7","author":"Vezzani","year":"2007","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.arr.2021.101496_bib455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101496_bib456","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1073\/pnas.172504199","article-title":"Amyloid beta -peptide inhibition of the PKA\/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling","volume":"99","author":"Vitolo","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib457","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial","author":"Vossel","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib458","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","article-title":"Seizures and epileptiform activity in the early stages of Alzheimer disease","volume":"70","author":"Vossel","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib459","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","article-title":"Epileptic activity in Alzheimer\u2019s disease: causes and clinical relevance","volume":"16","author":"Vossel","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib460","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.25455","article-title":"Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease","volume":"85","author":"Wadhwani","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib461","doi-asserted-by":"crossref","first-page":"n1682","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for Alzheimer's disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2021.101496_bib462","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","article-title":"Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector","volume":"24","author":"Wang","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.arr.2021.101496_bib463","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2021.101496_bib464","first-page":"262","article-title":"UB-311, a novel UBITh(\u00ae) amyloid \u03b2 peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib465","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2005.12.057","article-title":"Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons","volume":"398","author":"Wang","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2021.101496_bib466","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2020.04.025","article-title":"Genome-wide interaction analysis of pathological hallmarks in Alzheimer\u2019s disease","volume":"93","author":"Wang","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib467","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fnagi.2017.00243","article-title":"Enhanced gamma activity and cross-frequency interaction of resting-state electroencephalographic oscillations in patients with Alzheimer\u2019s disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib468","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib469","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.neurobiolaging.2007.12.004","article-title":"Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP\/PKA signalling pathway","volume":"30","author":"Wang","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib470","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s dementia","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101496_bib471","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101496_bib472","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.arr.2021.101496_bib473","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41467-018-04120-z","article-title":"C\/EBP\u03b2 regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer\u2019s disease","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2021.101496_bib474","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.06.054","article-title":"Deficiency in BDNF\/TrkB neurotrophic activity stimulates \u03b4-secretase by upregulating C\/EBP\u03b2 in Alzheimer\u2019s disease","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.arr.2021.101496_bib475","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-4159.2010.06615.x","article-title":"The amyloid precursor protein intracellular domain(AICD) disrupts actin dynamics and mitochondrial bioenergetics","volume":"113","author":"Ward","year":"2010","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2021.101496_bib476","first-page":"e1","article-title":"Recent publications from the Alzheimer\u2019s disease neuroimaging initiative: reviewing progress toward improved AD clinical trials","volume":"13","author":"Weiner","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib477","article-title":"Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease","volume":"6","author":"Weninger","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib478","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101496_bib479","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib480","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib481","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib482","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104742","article-title":"APOE alters glucose flux through central carbon pathways in astrocytes","volume":"136","author":"Williams","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101496_bib483","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101496_bib484","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101496_bib485","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","article-title":"A genetic cause of Alzheimer disease: mechanistic insights from down syndrome","volume":"16","author":"Wiseman","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib486","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2019.07.004","article-title":"Substrate recognition and processing by \u03b3-secretase","volume":"1862","author":"Wolfe","year":"2020","journal-title":"Biochim Biophys. Acta Biomembr."},{"key":"10.1016\/j.arr.2021.101496_bib487","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0896-6273(03)00840-7","article-title":"Cholesterol and the biology of Alzheimer's disease","volume":"41","author":"Wolozin","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib488","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0197-4580(95)02064-0","article-title":"The older rabbit as an animal model: implications for Alzheimer\u2019s disease","volume":"17","author":"Woodruff-Pak","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101496_bib489","unstructured":"World Health Organization, 2020. WHO reveals leading causes of death and disability worldwide: 2000\u20132019."},{"key":"10.1016\/j.arr.2021.101496_bib490","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40048","article-title":"Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease","volume":"7","author":"Xian","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.arr.2021.101496_bib491","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1073\/pnas.1901348116","article-title":"Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer\u2019s disease pathologies","volume":"116","author":"Xiang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101496_bib492","first-page":"1299","article-title":"Meta-analysis of modifiable risk factors for Alzheimer\u2019s disease","volume":"86","author":"Xu","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2021.101496_bib493","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jnr.21998","article-title":"NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus","volume":"87","author":"Yamin","year":"2009","journal-title":"J. Neurosci. Res"},{"key":"10.1016\/j.arr.2021.101496_bib494","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.19025","article-title":"Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic","volume":"184","author":"Yen","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.arr.2021.101496_bib495","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.18632\/aging.102516","article-title":"Apolipoprotein E regulates mitochondrial function through the PGC-1alpha-sirtuin 3 pathway","volume":"11","author":"Yin","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.arr.2021.101496_bib496","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2021.101496_bib497","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnagi.2018.00083","article-title":"NSAID exposure and risk of Alzheimer\u2019s disease: an updated meta-analysis from cohort studies","volume":"10","author":"Zhang","year":"2018","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib498","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fncel.2014.00427","article-title":"The \u03b3-secretase complex: from structure to function","volume":"8","author":"Zhang","year":"2014","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib499","doi-asserted-by":"crossref","first-page":"21948","DOI":"10.1038\/srep21948","article-title":"Impaired theta-gamma coupling in APP-deficient mice","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101496_bib500","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3233\/JAD-170879","article-title":"Amyloid-\u03b2 Induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer\u2019s disease","volume":"62","author":"Zhang","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101496_bib501","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1152\/jn.00485.2004","article-title":"Amyloid beta prevents activation of calcium\/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation","volume":"92","author":"Zhao","year":"2004","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.arr.2021.101496_bib502","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fnmol.2020.00137","article-title":"Targeting amyloidogenic processing of APP in Alzheimer\u2019s disease","volume":"13","author":"Zhao","year":"2020","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib503","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2017.09.003","article-title":"Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes","volume":"96","author":"Zhao","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101496_bib504","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520938585","article-title":"The effect of hormone replacement therapy on cognitive function in female patients with Alzheimer\u2019s disease: a meta-analysis","volume":"35","author":"Zhou","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"10.1016\/j.arr.2021.101496_bib505","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2174\/1567205013666160415154550","article-title":"APOE4 Induces site-specific Tau phosphorylation through calpain-CDK5 signaling pathway in EFAD-Tg mice","volume":"13","author":"Zhou","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2021.101496_bib506","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-neuro-080317-061725","article-title":"What happens with the circuit in Alzheimer\u2019s disease in mice and humans?","volume":"41","author":"Zott","year":"2018","journal-title":"Annu Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101496_bib507","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1126\/science.aay0198","article-title":"A vicious cycle of beta amyloid-dependent neuronal hyperactivation","volume":"365","author":"Zott","year":"2019","journal-title":"Science"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:57:53Z","timestamp":1761591473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163721002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":507,"alternative-id":["S1568163721002439"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2021.101496","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2021.101496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101496"}}